Telix Plans $1.65 Billion ITM Acquisition
Telix Plans $1.65 Billion ITM Acquisition
Anonymous
Key Points
1
The transaction structure includes the issuance of 105.8 million Telix shares to ITM sellers, priced at Telix’s 30-day trailing VWAP of US$11.841, while Telix will also assume approximately US$302 million in ITM net debt at closing.
2
ITM-11, also known as 177Lu-edotreotide, has completed the COMPETE Phase 3 trial and fully enrolled the COMPOSE Phase 3 study; an interim analysis from COMPOSE is expected in the first half of 2027.
3
Management expects the combined company to make a positive EBITDA contribution from 2027 onward, contingent on achieving planned synergies and commercial timing assumptions and excluding one-off implementation costs.
4
Telix’s existing portfolio includes Illuccix for PSMA-PET imaging, FDA-approved Gozellix and Pixclara, Scintimun approved in 32 European countries and Mexico, and the SENSEI surgical gamma probe; ITM also supplies the EMA-approved EndolucinBeta lutetium-177 product.
5
Telix said the securities issued as consideration, including American Depositary Shares, will not be registered under the U.S. Securities Act and may not be offered or sold in the United States without registration or an applicable exemption; the filing also identified planned NDA resubmission for ITM-11 and BLA resubmission for TLX250-Px.
Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical giant. The deal, paid mostly in Telix shares, could be worth up to US$2.35 billion if ITM-11 hits development milestones. The combined company projects 2026 revenue above US$1.3 billion and would control critical supply chains for cancer-fighting radioactive isotopes used in over 65 countries Marketscreener.
Telix will issue 105.8 million shares at US$11.841 per share and assume US$302 million in ITM debt. The deal blends Telix's drug development expertise with ITM's large-scale production of therapeutic radioisotopes like lutetium-177 and actinium-225. Telix shareholders will own 76.3% of the combined entity Kalkine.
ITM-11 Advances as Centerpiece Cancer Treatment
ITM-11, a late-stage drug for neuroendocrine tumors, is the deal's main prize. The treatment has completed a Phase 3 COMPETE trial and fully enrolled the COMPOSE Phase 3 study Marketscreener. An interim analysis is expected in the first half of 2027. The compound uses lutetium-177, a radioactive isotope that ITM produces at industrial scale.
ITM's 2025 Revenue and Global Supply Footprint
ITM reported US$273 million in 2025 revenue and operates commercial supply operations across more than 65 countries Kalkine. The Munich-based company produces therapeutic radioisotopes including lutetium-177, actinium-225, and terbium-161 for cancer treatments. It also supplies EndolucinBeta, an EMA-approved lutetium-177 product used by hospitals worldwide Marketscreener.
Telix's Existing Portfolio and Synergy Potential
Telix already markets Illuccix for PSMA-PET imaging and FDA-approved drugs Gozellix and Pixclara. The company also sells Scintimun in 32 European countries plus Mexico, and makes the SENSEI surgical gamma probe Marketscreener. By owning ITM's production capability, Telix can integrate upstream manufacturing with downstream drug sales and secure long-term isotope supplies.
Profitability Timeline and Shareholder Approvals Pending
Management expects the combined company to turn cash-flow positive from 2027 onward, assuming planned synergies and commercial milestones are met Marketscreener. The deal requires shareholder and regulatory approvals, with closing expected by the end of fiscal 2026. Telix also plans to resubmit its NDA for ITM-11 and BLA for TLX250-Px, expanding its drug pipeline Kalkine.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
25
Articles
151
Reach
176
A
AnonymousAuthor
